Dr IV - Assembly Biosciences Chief Officer
| ASMB Stock | USD 15.04 0.32 2.17% |
Insider
Dr IV is Chief Officer of Assembly Biosciences
| Age | 52 |
| Address | Two Tower Place, South San Francisco, CA, United States, 94080 |
| Phone | 833 509 4583 |
| Web | https://www.assemblybio.com |
Assembly Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3472) % which means that it has lost $0.3472 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0178) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Assembly Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 130.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeff York | Seres Therapeutics | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Hing Wong | HCW Biologics | 70 | |
| Lisa Miller | Lumos Pharma | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Bradley JD | Lumos Pharma | 45 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Carl Langren | Lumos Pharma | 69 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| David MBA | Seres Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
Management Performance
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.35 |
Assembly Biosciences Leadership Team
Elected by the shareholders, the Assembly Biosciences' board of directors comprises two types of representatives: Assembly Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assembly. The board's role is to monitor Assembly Biosciences' management team and ensure that shareholders' interests are well served. Assembly Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assembly Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicole White, Chief Officer | ||
| AO FRACP, CEO Director | ||
| Adam Zlotnick, Chief CoFounder | ||
| Jason Okazaki, President CEO | ||
| Amy CFA, Investor Consultant | ||
| Uri MD, CoFounder Advisor | ||
| Michele Anderson, Chief Officer | ||
| Dr IV, Chief Officer | ||
| Richard Colonno, Chief Scientific Officer | ||
| Jeanette Bjorkquist, Executive Treasury | ||
| Thomas Rollins, Chief Development Officer | ||
| Tharaknath Rao, Head VP | ||
| Shannon Ryan, Corporate Relations | ||
| MHROD SHRMSCP, Chief Officer | ||
| Anuj MD, Chief Officer |
Assembly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assembly Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.12) % | ||||
| Operating Margin | (1.43) % | ||||
| Current Valuation | 2.09 M | ||||
| Shares Outstanding | 6.36 M | ||||
| Shares Owned By Insiders | 31.62 % | ||||
| Shares Owned By Institutions | 18.79 % | ||||
| Number Of Shares Shorted | 7.95 K | ||||
| Price To Earning | (10.58) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share 4.125 | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (1.02) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.